title: Immune Cell Subsets Evaluation as a Predictive Tool for Hepatitis B Infection Outcome and Treatment Responsiveness.
abstract: BACKGROUND
  The patient's immune response is one of the major factors influencing HBV eradication or chronification, and it is thought to be responsible for the treatment success.
  
  
  OBJECTIVE
  Our study aimed to investigate whether cellular defense mechanisms are associated with the course of HBV infection (spontaneous recovery [SR] or chronification [CHB]) and with the therapeutic approach.
  
  
  METHODS
  A total of 139 patients (118 with CHB, 21 SR) and 29 healthy individuals (HI) were immunophenotyped by flowcytometry. Fifty-six patients were treatment-naïve, 20 were treated with interferons and 42 with nucleoside/ nucleotide analogues.
  
  
  RESULTS
  Deficiency of T lymphocytes, helper-inducer (CD3+CD4+), suppressorcytotoxic (CD8+CD3+) and cytotoxic (CD8+CD11b-, CD8+CD28+) subsets, activated T cells (CD3+HLA-DR+, CD8+CD38+) and increased CD57+CD8- cells, elevated percentages of B lymphocytes and NKT cells were observed in CHB patients compared with HI. In SR patients, elevated CD8+CD11b+, NKT and activated T cells were found in comparison with controls. The higher values of T cells and their subsets in SR patients than in CHB patients reflect a recovery of cellular immunity in resolved HBV infection individuals. In both groups of treated patients, reduced T lymphocytes, CD3+CD4+ and CD8+CD38+ subsets were found in comparison with HI. Higher proportions of cytotoxic subsets were observed in treated patients compared with treatment-naïve CHB patients, more pronounced in the group with interferon therapy.
  
  
  CONCLUSIONS
  Our data demonstrate that cellular immune profiles may be of prognostic value in predicting the clinical course of HBV infection, and the determination of the therapeutic response.
authors.affiliation: Department of Clinical Immunology and Stem Cell Bank, Alexandrovska University Hospital, Medical University of Sofia, 1 G. Sofiisky St. 1431 Sofia.
authors.forename: Snezhina M
authors.initials: SM
authors.lastname: Kandilarova
authors.affiliation: Department of Clinical Immunology and Stem Cell Bank, Alexandrovska University Hospital, Medical University of Sofia, 1 G. Sofiisky St. 1431 Sofia.
authors.forename: Atanaska I
authors.initials: AI
authors.lastname: Georgieva
authors.affiliation: Department of Clinical Immunology and Stem Cell Bank, Alexandrovska University Hospital, Medical University of Sofia, 1 G. Sofiisky St. 1431 Sofia.
authors.forename: Anastasiya P
authors.initials: AP
authors.lastname: Mihaylova
authors.affiliation: Department of Clinical Immunology and Stem Cell Bank, Alexandrovska University Hospital, Medical University of Sofia, Sofia.
authors.forename: Marta P
authors.initials: MP
authors.lastname: Baleva
authors.affiliation: Department of Clinical Immunology and Stem Cell Bank, Alexandrovska University Hospital, Medical University of Sofia, 1 G. Sofiisky St. 1431 Sofia.
authors.forename: Valentina K
authors.initials: VK
authors.lastname: Atanasova
authors.affiliation: Clinic of Propaedeutics of Internal Diseases, Alexandrovska University Hospital, Medical University of Sofia, Sofia.
authors.forename: Diana V
authors.initials: DV
authors.lastname: Petrova
authors.affiliation: Clinic of Infectious Diseases, Military Medical Academy, Sofia.
authors.forename: Georgi T
authors.initials: GT
authors.lastname: Popov
authors.affiliation: Department of Clinical Immunology and Stem Cell Bank, Alexandrovska University Hospital, Medical University of Sofia, 1 G. Sofi isky St. 1431 Sofia.
authors.forename: Elissaveta J
authors.initials: EJ
authors.lastname: Naumova
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D016175:B-Lymphocyte Subsets / Q000276:immunology*; D016022:Case-Control Studies; D018450:Disease Progression; D005260:Female; D005434:Flow Cytometry; D006509:Hepatitis B / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D055611:Natural Killer T-Cells / Q000276:immunology; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012075:Remission, Spontaneous; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a
keywords: HBV infection; cellular immune response; immunophenotyping